oalib
Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
NUEVA BENZOIL LACTONA Y OTROS CONSTITUYENTES DE Pilocarpus alvaradoii (Rutaceae)
Cuca,Luis E.; ávila,Mónica C.;
Revista Colombiana de Química , 2007,
Abstract: from the ethanolic extract of pilocarpus alvaradoii leaves was isolated and identified a new lactone α-benzoil-γ-valerolactone 1, along with the known pentacyclic triterpenoids lupeol 2, epibetulin 3; and the furanocoumarins bergapten 4, psoralen 5, and xantothoxin 6. isolation and purification were performed by chromatographic techniques. the structure compounds elucidation was accomplished by spectroscopic techniques (ir, rmn 1h, 13c and ms).
Results from TOTEM and ALFA  [cached]
Eggert Karsten
EPJ Web of Conferences , 2012, DOI: 10.1051/epjconf/20122802002
Abstract: Results from TOTEM and ALFA
Recombinant follitropin alfa/lutropin alfa in fertility treatment
Ahmed Gibreel, Siladitya Bhattacharya
Biologics: Targets and Therapy , 2010, DOI: http://dx.doi.org/10.2147/BTT.S3326
Abstract: ombinant follitropin alfa/lutropin alfa in fertility treatment Review (6292) Total Article Views Authors: Ahmed Gibreel, Siladitya Bhattacharya Published Date December 2009 Volume 2010:4 Pages 5 - 17 DOI: http://dx.doi.org/10.2147/BTT.S3326 Ahmed Gibreel1, Siladitya Bhattacharya2 1School of Medicine and Dentistry, University of Aberdeen; 2Aberdeen Maternity Hospital, Aberdeen, UK Abstract: Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone (LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engineering techniques which ensure high quality and batch to batch consistency. Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory infertility and in men with hypogonadotrophic hypogonadism (HH) or idiopathic oligo-asthenospermia. Current evidence suggests superiority of urinary human menopausal gonadotropin (HMG) over follitropin alpha in controlled ovarian hyperstimulation for IVF in terms of live birth rate per couple. Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism. Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy. However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes.
The ALFA Laser and Analysis Tools  [PDF]
S. Rabien,T. Ott,W. Hackenberg,A. Eckart,R. Davies,M. Kasper,A. Quirrenbach
Physics , 1999,
Abstract: The optimal performance of adaptive optics systems can only be maintained if the wavefront reference is bright and compact. Experience has shown that both of these important criteria are remarkably difficult to achieve with laser guide stars, and this contribution gives an account of the methods by which ALFA attempts to reach them. First, the production of a high quality, high power laser beam is described. However, this quality is unavoidably compromised along the path to the launch telescope. In order to rectify this, a new set of diagnostic tools which monitor the quality of the out-going beam has been installed, and these are also described. Lastly, we outline a number of possible modifications on which we are working. If successful, these may allow a substantial improvement in the beam quality.
PRODUCTION OF DISSOLVING GRADE PULP FROM ALFA  [PDF]
Baya Bouiri,Moussa Amrani
BioResources , 2010,
Abstract: Alfa, also known as Stipa tenacissimaI or “halfa”, is grown in North Africa and south Spain. Due to its short fiber length, paper made from alfa pulp retains bulk and takes block letters well. In this study alfa was evaluated for bleached pulp production. Two cellulose pulps with different chemical compositions were pulped by a conventional kraft process. One sample was taken from the original alfa material and another from alfa that had been pretreated by diluted acid. The pulp produced from the pretreated alfa was bleached by the elemental-chlorine-free sequences DEPD and DEDP. The yield, Kappa number, brightness, and α- cellulose content of bleached and unbleached pulps were evaluated. The results showed that during the chemical pulping process, treated alfa cooked more easily than the original alfa. The treated alfa pulp also showed very good bleaching, reaching a brightness level of 94.8% ISO with a yield of 93.6% at an α-cellulose content 96.8(%) with a DEDP bleaching sequence, compared to 83.2% ISO brightness level, 92.8% yield, and 95.1% α-cellulose content for bleached pulp with a DEPD bleaching sequence. Therefore, this alfa material could be considered as a worthwhile choice for cellulosic fiber supply.
Conestat alfa for the treatment of angioedema attacks
Davis B, Bernstein JA
Therapeutics and Clinical Risk Management , 2011, DOI: http://dx.doi.org/10.2147/TCRM.S15544
Abstract: nestat alfa for the treatment of angioedema attacks Review (3523) Total Article Views Authors: Davis B, Bernstein JA Published Date July 2011 Volume 2011:7 Pages 265 - 273 DOI: http://dx.doi.org/10.2147/TCRM.S15544 Benjamin Davis, Jonathan A Bernstein University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati, OH, USA Abstract: Recently, multiple C1 inhibitor (C1-INH) replacement products have been approved for the treatment of hereditary angioedema (HAE). This review summarizes HAE and its current treatment modalities and focuses on findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement products because it is produced from transgenic rabbits rather than derived from human plasma donors, which can potentially allow an unlimited source of drug without any concern of infectious transmission. The clinical trial data generated to date indicate that conestat alfa is safe and effective for the treatment of acute HAE attacks.
ALFA: an automated line fitting algorithm  [PDF]
Roger Wesson
Physics , 2015,
Abstract: I present the Automated Line Fitting Algorithm, ALFA, a new code which can fit emission line spectra of arbitrary wavelength coverage and resolution, fully automatically. In contrast to traditional emission line fitting methods which require the identification of spectral features suspected to be emission lines, ALFA instead uses a list of lines which are expected to be present to construct a synthetic spectrum. The parameters used to construct the synthetic spectrum are optimised by means of a genetic algorithm. Uncertainties are estimated using the noise structure of the residuals. An emission line spectrum containing several hundred lines can be fitted in a few seconds using a single processor of a typical contemporary desktop or laptop PC. I show that the results are in excellent agreement with those measured manually for a number of spectra. Where discrepancies exist, the manually measured fluxes are found to be less accurate than those returned by ALFA. Together with the code NEAT (Wesson et al. 2012), ALFA provides a powerful way to rapidly extract physical information from observations, an increasingly vital function in the era of highly multiplexed spectroscopy. The two codes can deliver a reliable and comprehensive analysis of very large datasets in a few hours with little or no user interaction.
Interferon alfa a opryszczkowate zapalenie skóry
Marian Dmochowski,Danuta Januszkiewicz-Lewandowska,Monika Bowszyc-Dmochowska
Clinical Dermatology , 2007,
Abstract: Przedstawiono kolejny przypadek opryszczkowatego zapalenia skóry prawdopodobnie ujawnionego po zastosowaniu interferonu alfa. Interferon alfa mo e uczynnia neutrofile u tych chorych. Przypadek ten sugeruje, e autoimmunizacja wobec transglutaminazy naskórkowej rozwija si równie u takich chorych.
Conestat alfa for the treatment of angioedema attacks
Davis B,Bernstein JA
Therapeutics and Clinical Risk Management , 2011,
Abstract: Benjamin Davis, Jonathan A BernsteinUniversity of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati, OH, USAAbstract: Recently, multiple C1 inhibitor (C1-INH) replacement products have been approved for the treatment of hereditary angioedema (HAE). This review summarizes HAE and its current treatment modalities and focuses on findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement products because it is produced from transgenic rabbits rather than derived from human plasma donors, which can potentially allow an unlimited source of drug without any concern of infectious transmission. The clinical trial data generated to date indicate that conestat alfa is safe and effective for the treatment of acute HAE attacks.Keywords: androgens, adverse events, patients, HAE attacks
Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats
Michael Alper, Randal Meyer, Chris Dekkers, Diego Ezcurra, Joan Schertz, Eduardo Kelly
Reproductive Biology and Endocrinology , 2008, DOI: 10.1186/1477-7827-6-31
Abstract: The biopotencies of r-hFSH and r-hLH were determined following injection of female Sprague-Dawley rats with a mixture of follitropin alfa revised formulation female (RFF) and lutropin alfa (1:1, r-hFSH:r-hLH). Biopotencies of follitropin alfa RFF and lutropin alfa were measured using ovarian weight and ascorbic acid depletion assays, respectively, and compared with a reference standard. Stock mixtures of follitropin alfa RFF and lutropin alfa (1:1) were prepared within 1 h prior to each respective assay's injection and stored at 6 +/- 2°C. Separate low dose (follitropin alfa RFF 1.5 IU/rat, lutropin alfa 2 IU/rat) and high dose (follitropin alfa RFF 3 IU/rat, lutropin alfa 8 IU/rat) treatments were prepared from stock mixtures or individual solutions by diluting with 0.22% bovine serum albumin saline solution and injected within 1 h of preparation. The main outcome measures were ovarian weight and ovarian ascorbic acid depletion.FSH bioactivities were similar (p > 0.10) between the individual follitropin alfa RFF test solution (84.2 IU) and follitropin alfa RFF/lutropin alfa (87.6 IU) mixtures prepared within 1 h of injection and stored at 6 +/- 2°C. LH bioactivities were similar (p > 0.10) between lutropin alfa (94.7 IU) test solution and lutropin alfa/follitropin alfa RFF (85.3 IU) mixtures prepared within 1 h of injection and stored at 6 +/- 2°C for not more than 1 h prior to injection.Mixing follitropin alfa RFF and lutropin alfa did not alter the bioactivity of either FSH or LH.In 1988, human follicle-stimulating hormone (hFSH) was successfully expressed using Chinese hamster ovary cells, representing the initial steps for commercial development of gonadotropin products originating from recombinant deoxyribonucleic acid (r-DNA) technology [1]. The first recombinant hFSH, GONAL-f? (r-hFSH, follitropin alfa for injection), was licensed in 1995 for marketing in the European Union [2]. By the turn of the century, recombinant human luteinizing hormone (r-hLH, lutrop
Page 1 /100
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.